德国某医院ICU内利奈唑胺耐药表皮葡萄球菌的出现与控制
该研究调查了德国某跨学科ICU内15个月内14例患者利奈唑胺耐药表皮葡萄球菌(LRSE)定植或感染的暴发,分析菌株克隆相关性、耐药机制及cfr质粒特征,并评估利奈唑胺用量与感染控制措施。分子分型发现三个LRSE克隆群,10株携带cfr基因,不同遗传背景菌株中检出几乎相同的39 kb cfr质粒;2014年1月至7月利奈唑胺用量从5.55升至20.41 DDDs/100患者日。结论认为减少利奈唑胺使用和加强接触隔离是有效的感染控制措施。
要点
- 15个月内14例患者出现LRSE定植或感染,分子分型发现三个不同克隆群。
- 10株LRSE携带cfr基因,不同遗传背景菌株中检出几乎相同的39 kb cfr质粒。
- 减少利奈唑胺用量和加强接触隔离被证明是有效的感染控制措施。
核心结论
- 结果提示利奈唑胺治疗下耐药突变株被选择,同时携带cfr的质粒发生播散。
- 减少利奈唑胺用量和加强接触隔离被证明是有效的感染控制措施。
研究设计与样本
- 对德国某医院跨学科ICU内15个月期间14例LRSE定植或感染患者进行暴发调查。
- 对LRSE分离株进行克隆相关性、抗菌药物敏感性、cfr基因及23S rRNA、rplC、rplD、rplV基因突变分析,cfr质粒用Illumina测序表征。
- 回顾病历并统计抗生素消耗量。
主要发现
- 分子分型鉴定出三个LRSE克隆群:PFGE I型/ST168(n=5)、PFGE II型/ST5(n=10)、PFGE III型/ST2(n=1)。
- 10株菌携带cfr基因,同时在相应核糖体蛋白基因中检出突变。
- 全基因组测序显示来自不同遗传背景(ST2、ST5、ST168)菌株的几乎相同的39 kb cfr质粒,与近期发表的LRSE质粒p12-02300高度相似。
- 因MRSA感染治疗患者数增加,2014年1月至7月利奈唑胺用量从5.55升至20.41 DDDs/100患者日。
临床怎么用
- 作者报告了ICU内LRSE的分子流行病学,结果提示利奈唑胺治疗下耐药突变株被选择及携带cfr质粒的播散。
- 减少利奈唑胺用量和加强接触隔离被证明是有效的感染控制措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate an outbreak of linezolid-resistant Staphylococcus epidermidis (LRSE) in an interdisciplinary ICU, linezolid consumption and infection control measures taken. METHODS: Routine surveillance of nosocomial infections revealed colonization and infection with LRSE affecting 14 patients during a 15 month period. LRSE isolates were analysed with respect to their clonal relatedness, antimicrobial susceptibility, the presence of cfr and/or mutations in the 23S rRNA, rplC, rplD and rplV genes. cfr plasmids were characterized by Illumina sequencing. Medical records were reviewed and antibiotic consumption was determined. RESULTS: Molecular typing identified the presence of three different LRSE clusters: PFGE type I/ST168 (n = 5), PFGE type II/ST5 (n = 10) and PFGE type III/ST2 (n = 1). Ten strains harboured the cfr gene; we also detected mutations in the respective ribosomal protein genes. WGS revealed an almost identical 39 kb cfr plasmid obtained from strains of different genetic background (ST2, ST5, ST168) that shows high similarity to the recently published LRSE plasmid p12-02300. Due to an increase in the number of patients treated for infections with MRSA, a significant increase in linezolid usage was noted from January to July 2014 (from 5.55 to 20.41 DDDs/100 patient-days). CONCLUSIONS: Here, we report the molecular epidemiology of LRSE in an ICU. Our results suggest the selection of resistant mutants under linezolid treatment as well as the spread of cfr-carrying plasmids. The reduction of linezolid usage and the strengthening of contact precautions proved to be effective infection control measures.
引用
- Weßels C, Strommenger B, Klare I, et al. Emergence and control of linezolid-resistant Staphylococcus epidermidis in an ICU of a German hospital. J Antimicrob Chemother. 2018. PMID: 29438544. doi:10.1093/jac/dky010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。